Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in the context of hyperparathyroidism in this randomized controlled trial publication.

Cinacalcet and vitamin D are often combined to treat secondary hyperparathyroidism (SHPT) in patients on dialysis.

Independent effects on fibroblast growth factor-23 (FGF-23) concentrations in patients on hemodialysis administered cinacalcet or vitamin D analogs as monotherapies during treatment of SHPT are evaluated.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

Correlations and logistic regression were used to explore relationships between changes in FGF-23 and changes in PTH, Ca, P, and Ca×P from baseline to week 52 by treatment arm.

How the Study Was Run

The design is described as randomized, open-label and multicenter.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Nothing was hidden in this open-label Vitamin D, K2, Magnesium and Zinc study: the participants and staff both knew the treatment.

Running at several centres spread the Vitamin D, K2, Magnesium and Zinc study over different clinics and patient groups.

Levels of FGF-23 were measured at baseline and weeks 20 and 52.

The absolute and percentage changes from baseline in plasma FGF-23, parathyroid hormone (PTH), calcium (Ca), phosphorus (P), and calcium-phosphorus product (Ca×P) were assessed.

What Was Measured

The subject headings attached to it are Australia, Biomarkers, Calcimimetic Agents, Calcium, Canada, Chi-Square Distribution and Cinacalcet.

The authors tagged it with the keywords ESRD, clinical nephrology, dialysis and hyperparathyroidism.

What This Means in Plain Language

The paper is a randomized, open-label and multicenter study of Vitamin D, K2, Magnesium and Zinc in people with hyperparathyroidism.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2015 (Clinical journal of the American Society of Nephrology : CJASN), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, Hyperparathyroidism research.